Johnson & Johnson (JNJ)

Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives.

Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.

Johnson & Johnson shared positive ASCO 2025 results, including improved survival and remission in prostate and multiple myeloma patients.

These stocks are ready for a summer surge.

For long-term investors looking for both stability and innovation in the healthcare space, JNJ is a rare combination of both.

Michael Mahoney's grandfather was a cardiac surgeon — so his first career plan was to become a doctor. Mahoney didn't give up — he adjusted.

Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design.

Activist investor Dan Loeb's Third Point LLC acquired a significant stake in consumer health company Kenvue Inc. in Q1 2025.

Johnson & Johnson (NYSE:JNJ) offers a strong dividend yield, consistent growth, and solid profitability, making it a compelling choice for income investors.

For buy-and-hold investors looking for some quality names to navigate a turbulent market, here are three stocks to consider

US companies are reshoring manufacturing operations & investing billions in the country, led by Apple & Nvidia for tech, J&J & Eli Lilly for healthcare, Anheuser-Busch for beer, & Cra-Z-Art for toys. Detroit & beyond are benefiting from this trend.

Warren Buffett has had a lot of successful investments, but one in particular has crushed the stock market time and again.

U.S. and China cut tariffs by 115 points, sparking a stock rally and improving trade outlook. Trump secures $2 trillion in Gulf deals.

For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity.